The goal of this study is to investigate the prevalence of dysglycemia with continuous glucose monitoring (CGM) obtained during pulmonary exacerbations, both outpatient and inpatient, in youth with cystic fibrosis (CF).
This research is using continuous glucose monitoring (CGM) to study changes in blood sugar levels that may occur in youth with cystic fibrosis (CF) and cystic fibrosis related diabetes (CFRD) who experience a pulmonary exacerbation (PEx), whether admitted to the hospital or seen in clinic. We hypothesize that 1) youth experiencing a PEx will have greater blood sugar changes during the PEx than at least 6 weeks after the PEx , 2) that the changes in blood sugars will be greater during the PEx when compared to CGM data gathered at a baseline visit prior to the PEx (when available), 3) and that blood sugar changes during the PEx will compare with changes in short-term clinical outcomes collected using questionnaires about breathing problems, and that this data will be predictive of the need for additional antibiotics. This study aims to compare CGM measures of change during a PEx with those measured after recovery; to compare CGM measures of change during the PEx to those taken at baseline; and to examine the relationships between these changes and the changes in clinical findings including the need for additional antibiotics.
Study Type
OBSERVATIONAL
Enrollment
50
Children's Hospital Colorado, University of Colorado Denver
Aurora, Colorado, United States
RECRUITINGCGM standard deviation
Measures of glycemic variability from CGM during the exacerbation (CGM-PEx) compared measure derived from recovery period (CGM-post)
Time frame: 14 days
CGM coefficient of variation
CGM measure of glycemic variability during the exacerbation (CGM-PEx) with recovery measure (CGM-post)
Time frame: 14 days
MAGE (mean amplitude of glycemic excursions)
CGM measures of glycemic variability (MAGE) during the exacerbation (CGM-PEx) with recovery measures (CGM-post)
Time frame: 14 days
Forced expiratory volume at one second (FEV1) at each visit
Collected clinically at baseline during routine visits, and at the start of a pulmonary exacerbation (PEx) for those admitted inpatient and in clinic, and at next in person routine clinic visit; b)by home spirometer during routine clinic visits, and in the hone setting (if not in person) once for the baseline visit, and at the onset of exacerbation and twice/week for 14 days, and once upon recovery (at least 6 weeks after PEx)
Time frame: up to 2 years
Need for additional antibiotics within 28 days following initial treatment
If initial Rx for antiobiotics proves unsuccessful and participant requires additional treatment
Time frame: up to 2 years
Chronic Respiratory Infection Symptom Score questionnaire
Questionnaire tracking exacerbation symptoms
Time frame: up to 2 years
sputum culture as available from clinical data
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Will be collected when available from clinical data
Time frame: up to 2 years
markers of inflammation when available
hsCRP (highly sensitive C-Reactive Protein) and cytokines (eg; Interleukin-6 \[IL 6\] \& Interleukin-8 \[IL8\]) at visits
Time frame: up to 2 years
Cystic Fibrosis Questionnaire Revised (CFQR) questionnaire
quality of life questionnaire
Time frame: up to 2 years